Cyclosporine controls epidermolysis bullosa acquisita co-occuring with acquired factor VIII deficiency

John C. Maize, Jack B. Cohen

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Background: Epidermolysis bullosa acquisita (EBA) is a rare antibody-mediated autoimmune blistering disease of adults. Likewise, acquired factor VIII deficiency is a rare antibody-mediated disease of adulthood. Both diseases can be exceedingly difficult to treat and refractory to immunomodulatory therapies. Methods: Herein, we report a challenging case of EBA and acquired factor VIII deficiency in the same patient. Results: Cyclosporine 4 mg/kg/day rapidly controlled both disease processes after the patient failed to respond to prednisone, colchicine, and pulse cyclophosphamide. The EBA relapsed when the cyclosporine was decreased to 2 mg/kg/day and the patient wore snuggly fitting new shoes, but it cleared quickly when the dose was increased. Cyclosporine has since been decreased gradually to 1.5 mg/kg/day without relapse of either condition or detectable side-effects. Conclusions: Cyclosporine should be considered when EBA and/or acquired factor VIII deficiency fail to respond to conservative therapy. Both conditions usually respond rapidly to cyclosporine 4-6 mg/kg/day.

Original languageEnglish (US)
Pages (from-to)692-694
Number of pages3
JournalInternational Journal of Dermatology
Issue number8
StatePublished - Aug 1 2005

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Cyclosporine controls epidermolysis bullosa acquisita co-occuring with acquired factor VIII deficiency'. Together they form a unique fingerprint.

Cite this